Expertise in
1
conditions

Hiltje De Graaf

Leeuwarden, FR, NL 
Expertise in
1
conditions
Leeuwarden, FR, NL 

Overview

Hiltje De Graaf practices practicing medicine in Leeuwarden, Netherlands.

De Graaf is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Breast Cancer, Amenorrhea, Postmenopausal Osteoporosis, and Osteoporosis.

They are actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 4 clinical trials.

Locations

Leeuwarden, FR, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Cyclophosphamide, atezolizumab, Paclitaxel
Study Phase: Phase 2
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drug: PTC-Pz
Study Phase: Phase 2
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
View 3 Less Clinical Trials

17 Total Publications

The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Journal: JNCI cancer spectrum
Published: July 05, 2023

Frequently Asked Questions about Hiltje De Graaf

Is Hiltje De Graaf a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Hiltje De Graaf is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hiltje De Graaf participate in research or clinical trials?

Yes. Hiltje De Graaf has published 17 articles and abstracts on conditions like Breast Cancer. You can view a list of Hiltje De Graaf's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find De Graaf's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile